SEC Filing Summary

Coleen Glessner, EVP, Quality & Ethics, and CPL at Emergent BioSolutions Inc. (EBS), was granted 100,111 restricted stock units on April 29, 2026. This grant, approved by the Compensation Committee and subject to stockholder approval of the Amended Stock Incentive Plan, represents a total of 204,219 shares post-transaction. The restricted stock units vest in three annual installments, assuming continued service with the company. Each unit entitles the holder to one share of common stock, subject to adjustments.